*Sponsored

*Corrected Disclosure Below

Breaking News Sends Low Float (Nasdaq: HIND) Up As Much As Approx. 130% Early Wednesday

September 17th

Greetings Readers,

Vyome Holdings, Inc. (Nasdaq: HIND) has taken control of my top watchlist spot this morning.

HIND has been up as much as approx. 130% on the heels of breaking news! Check it out:

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3Bn Addressable Market Opp.

Vyome’s offering is a first-of-its-kind in a broader $20Bn potential addressable ocular inflammation market

VT-1908 eyedrop achieves the desired concentration in the anterior chamber of the eye and significantly reduces uveitis score in preclinical models (P<0.001)

CAMBRIDGE, Mass., September 17, 2025–(BUSINESS WIRE)–Vyome Holdings, Inc. (Nasdaq: HIND), …, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1).

Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States alone (2), making it a roughly $3Bn market opp. by 2032. Steroids are the first line of treatment for uveitis, but many patients do not respond, and steroid use causes major complications, including cataract and increased pressure in the eye, leading to glaucoma. There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need. The broader addressable global market to treat inflammation in the eye is expected to exceed $20Bn by 2030 (5).

…

“Inflammation is one of the biggest problems of our time, which is often linked to the immune system, and we are addressing the root cause in tangible and specific applications in the eye. The fact that VT-1908 is as effective as a steroid is exciting as we can aim to replace steroids in the eye, which are associated with a number of complications,” said Dr. Shiladitya Sengupta, Co-Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “A large number of patients cannot even use steroids, and our results offer hope that a breakthrough treatment is potentially on the horizon for such patients with uveitis. Our preclinical results support advancing VT-1908 into the clinics.”

…

Read the full article here.

Take a moment to review my initial report below, the news above, and consider (Nasdaq: HIND) for your watchlist.

—–

A dynamic player in the heal.thcare and biotechnology space has recently gained added visibility with its inclusion on the Nasdaq Capital Market.

This step not only broadens its market presence but also enhances awareness around its mission of addressing critical unmet needs in dermatology and infectious disease.

The company continues to advance specialized treatments through a unique scientific platform, with a focus on solutions that extend beyond conventional approaches.

This expanded exposure and a clear path forward may work to capture greater attention, making now an ideal time to take a closer look at the progress being made.

And with a tiny float which could lead to explosive volatility potential, oversold technicals suggesting a healthy reversal/bounce may be nearing, and positive interim data for a key phase 2 study recently announced, this under-the-radar Nasdaq idea has risen to the top of my watchlist:

Vyome Holdings, Inc. (Nasdaq: HIND)

Vyome is building the world’s premier platform spanning the US-India innovation corridor.

Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions.

And based on several potential catalysts, (Nasdaq: HIND) takes over the top spot on my watchlist. Check them out:

#1. A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.

#2. Oversold Leaning Technicals May Suggest A Healthy Reversal/Bounce Could Be Approaching.

#3. Positive Interim Data From Key Phase 2 Study Helps Vyome Come That Much Closer To A Breakthrough Treatment.

#4. A Signed MoU Sets Vyome On A Path To Jointly Pursue A Booming Global AI-Enabled Med-Device Market.

#5. Visibility Help Could Grow Significantly With Vyome’s Addition To The Nasdaq Capital Market.

But more on those in a second…

Building the Future of Healthcare and Biotech Across Borders

Vyome Holdings was founded with a simple but ambitious vision: to tackle the hardest problems in heal.thcare—those overlooked, underserved, or resistant to existing treatments.

What began as a biotech company focused on immuno-inflammatory disease has grown into a diversified heal.thcare platform spanning pharma, medical devices, and AI in heal.thcare.

The company is a cross-border ecosystem of science, strategy, and scale. With a presence in both the United States and India, they unite world-class researchers, operators, and in-vest-ors around a shared goal: creating therapies and technologies that make a tangible difference for patients.

Vyome’s Reach

Biotech

• Differentiated therapies targeting immuno-inflammatory, rare, and resistant conditions.

Medical Devices

• Planning to acquire Proven technologies scaled globally.

AI in Heal.thcare

• Planning to acquire Data-driven solutions to improve decision-making and outcomes.

Featured Programs

Malignant Fungating Wounds (MFW)

Program: VT1953 Gel

Status: Clinical Development

Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.

VT1953 is a first-in-class gel designed to:

• Target DNA-gyrase to reduce the bacterial drivers of malodor.
• Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.

With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway.

—–

Uveitis

Program: VT1908 Eye Drops

Status: Preclinical Development

Uveitis is a leading cause of blindness, with current treatments dominated by steroids—yet many patients are non-responders or steroid-incompatible due to side effects and contraindications.

VT1908 is a novel sterile eye drop that:

• Inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme driving immune cell activity.
• Demonstrated comparable efficacy to steroids in preclinical uveitis models.
• Offers a promising alternative for patients who cannot tolerate existing therapies.

This program is advancing toward clinical development with the potential to redefine treatment standards in immune-related eye disease.

Grab Source And More Here: HIND Website.

—–

And as I mentioned earlier in the report, (Nasdaq: HIND) has several potential catalysts on our radar. Take a look:

#1. HIND Potential Catalyst – A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.

According to the Finviz website, HIND has a very low float.

In fact, the website reports this profile to have approximately 670K shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

If the company provides more positive company news in the 2nd half of 2025, could it create a near term spark?

—–

#2. HIND Potential Catalyst – Oversold Leaning Technicals May Suggest A Healthy Reversal/Bounce Could Be Approaching.

At 3:00PM EST Tuesday, Barchart was reporting HIND to have several oversold leaning technical indicators.

These technicals could be signaling a healthy reversal is approaching in the near term.

Here’s the definition of a “reversal” from Investopedia:

“A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart.”

Here’s the technicals to pay close attention to (as of 3:00PM EST Tuesday):

• 9-Day Relative Strength Index: 25.58%
• 14-Day Relative Strength Index: 33.95%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

• 14-Day Raw Stochastic: 0.58%

As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

—–

#3. HIND Potential Catalyst – Positive Interim Data From Key Phase 2 Study Helps Vyome Come That Much Closer To A Breakthrough Treatment.

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW Market Opp.

VT-1953 continues to significantly improve the primary endpoint

Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference

VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality of Life (P<0.001), both secondary and exploratory endpoints, respectively.

CAMBRIDGE, Mass., September 04, 2025–(BUSINESS WIRE)–Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage heal.thcare holding company, today announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds (“MFW”). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8, to share more about the preliminary results and the MFW market in advance of full results, which are expected in October 2026.

…

“Despite a large number of cancer patients suffering from the symptoms of MFW, there are no FDA-approved options for MFW,” said Dr. Sengupta, Co-founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “These early observations suggest VT-1953 is meeting the clinical benchmarks to advance further in clinical trials, and offer hope that a breakthrough treatment is potentially on the horizon for patients with MFW. I am excited to discuss our interim results further on Monday, September 8, 2025 as well as our plan for upcoming milestones for this particular application.”

Venkat Nelabhotla, CEO of Vyome, stated: “We are excited with the interim efficacy signals and to share more about the MFW market opp. MFW is a large, unmet addressable potential market opp. of $1Bn in the United States alone, offering the opp. to clinically develop and commercialize VT-1953 to positively impact patient lives. Based on our data, Vyome anticipates interacting with the FDA in early 2026. I look forward to advancing this program as part of our broader chronic immune-inflammation portfolio.”

…

Read the full article here.

—–

#4. HIND Potential Catalyst – A Signed MoU Sets Vyome On A Path To Jointly Pursue A Booming Global AI-Enabled Med-Device Market.

Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio

Vyome seeks to access multi-Bn-dollar AI-enabled medical device market

CAMBRIDGE, Mass. & PUNE, India, August 21, 2025–(BUSINESS WIRE)–Vyome Holdings, Inc. (Nasdaq: HIND), …, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome’s heal.thcare industry experience and resources with Embryyo’s medical technology capabilities to potentially productize and commercialize smart medical devices that can transform the standard-of-care in disease management and treatment.

“Vyome’s vision is to partner with the smartest talent tackling the biggest heal.thcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opp. and the Embryyo team – helmed by Indian Institutes of Technology (IIT) alums – has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner,” said Krishna Gupta, Chairman of Vyome Holdings.

…

Read the full article here.

—–

#5. HIND Potential Catalyst – Visibility Help Could Grow Significantly With Vyome’s Addition To The Nasdaq Capital Market.

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation Partnership

CAMBRIDGE, Mass., August 15, 2025–(BUSINESS WIRE)–Vyome Holdings (Nasdaq: HIND), …, will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as “HIND.” The occasion will also mark India’s 79th Independence Day.

“The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our st-ock being on Nasdaq,” said Krishna Gupta, Chairman of Vyome. “Our commitment to shareholders is simple: every decision we make will be in their best interests because we have no debt and because our board is smart and heavily aligned with shareholders.”

“Our innovation pipeline is very deep and we have access to world-class talent in both the US and India,” said Shiladitya Sengupta, Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “Our immediate focus will be to unlock the value of our clinical stage assets that all revolve around major unmet needs in the $100Bn immuno-inflammatory market, but our vision extends well beyond that.”

…

Read the full article here.

—–

(Nasdaq: HIND) Recap – 5 Potential Catalysts Lead The Way!

#1. A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.

#2. Oversold Leaning Technicals May Suggest A Healthy Reversal/Bounce Could Be Approaching.

#3. Positive Interim Data From Key Phase 2 Study Helps Vyome Come That Much Closer To A Breakthrough Treatment.

#4. A Signed MoU Sets Vyome On A Path To Jointly Pursue A Booming Global AI-Enabled Med-Device Market.

#5. Visibility Help Could Grow Significantly With Vyome’s Addition To The Nasdaq Capital Market.

—–

Coverage is now officially kicked-off on Vyome Holdings, Inc. (Nasdaq: HIND).

Be on your toes and keep your eyes peeled for updates coming soon.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/16/2025 and ending on 09/17/2025 to publicly disseminate information about (HIND:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither SWN Media LLC, TD Media LLC and their member own shares of (HIND:US).

Please see important disclosure information here: https://stockwirenews.com/disclosure/hind-1nyww/#details